BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21949640)

  • 1. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.
    Salzman J; Marinelli RJ; Wang PL; Green AE; Nielsen JS; Nelson BH; Drescher CW; Brown PO
    PLoS Biol; 2011 Sep; 9(9):e1001156. PubMed ID: 21949640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.
    Micci F; Panagopoulos I; Thorsen J; Davidson B; Tropé CG; Heim S
    PLoS Biol; 2014 Feb; 12(2):e1001784. PubMed ID: 24504521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
    Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
    BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
    Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
    Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
    Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
    Elattar A; Warburton KG; Mukhopadhyay A; Freer RM; Shaheen F; Cross P; Plummer ER; Robson CN; Edmondson RJ
    Gynecol Oncol; 2012 Jan; 124(1):142-7. PubMed ID: 22001143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
    Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
    J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Agostini A; Brunetti M; Davidson B; Göran Tropé C; Heim S; Panagopoulos I; Micci F
    Int J Cancer; 2018 Sep; 143(6):1379-1387. PubMed ID: 29633253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival.
    Sankaranarayanan P; Schomay TE; Aiello KA; Alter O
    PLoS One; 2015; 10(4):e0121396. PubMed ID: 25875127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
    Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
    BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
    Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
    Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer.
    Newtson A; Reyes H; Devor EJ; Goodheart MJ; Bosquet JG
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.